Igenomix has launched Embrace, a non-invasive test for prioritizing embryo transfer. Embrace scores embryos according to their probability of being healthy and viable based on chromosomal information. Rather than removing cells from a developing embryo through biopsy, Embrace enables scientists at Igenomix to use next-generation sequencing to test the drop of the culture medium in which a six-day-old embryo, or blastocyst, has developed to count the chromosome number of the embryonic cell-free DNA. A score is then given to determine the probability of the embryo being healthy and viable, the company said. According to the company the test will enable embryonic chromosome analysis to be accessible to a larger number of in vitro fertilization centers and patients, as it simplifies the process and increases chances of IVF success. Igenomix said that it is offering Embrace to the 400 US fertility centers it currently works with.